Yemaachi Biotech

Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche

Roche has signed as the founding partner to initiate the consortium which will generate genomic and clinical data from up to 7,500 African cancer patients ACCRA, Ghana & WASHINGTON–(BUSINESS WIRE)–Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Cancer Atlas (TACA). This initiative aims […]

Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases

Emmanuella Amoako abc, Setor Amuzu a, Emmanuel Owusu Ofori b, Harry Sefoga Akligoh a, Randy Tackie a, Barikisu Anna Ibrahim a, Emmanuel Kofi Quaye a, Patrick Kafui Akakpo bcd, Luke Adagrah Aniakwo b, Bashiro Jimah bc, Kofi Ulzen-Appiah bc, David Hutchful a, Aida Manu a, Joyce M Ngoi a, Lily Paemka a, Yakubu Alhassan ae, Ernest Amo Obeng d, Nicole Lim f, Lisa Rajah f, Michelle Pek f…Yaw Bediako a Transl Oncol; 49: 102100, 2024 Nov, https://doi.org/10.1016/j.tranon.2024.102100 Abstract Purpose: Breast cancer is a major cause of cancer-related mortality among African women. The adoption of molecular genomic technologies in the management of cancer cases is limited in Africa. To provide much-needed insights on the feasibility and utility […]

Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines

Our research on the COURAGE cohort of our Heritage Study has been published in BMC Rheumatology! The COvid-19 vaccine immUne Response in Autoimmune rheumatic patients: a Ghanaian Experience (COURAGE) study, led by Dr. Ida Dzifa Dey, followed 38 patients with Systemic lupus erythematous (SLE) and Rheumatoid arthritis (RA) over 12 months at Korle-Bu Teaching Hospital, to access changes in clinical disease activity following COVID-19 vaccination, and to understand vaccine immune response in this subset.